| Nov 2026 | Idebenone in REM sleep behaviour disorder | Behind the scenes | Trial methods & regulation | 2 | 28 | NCT04534023 | 22 Oct 2026 |
| Nov 2026 | TB006 (galectin-3 antibody) | Look beyond the brain | Inflammation & immunity | 2 | 62 | NCT06773962 | 19 Oct 2026 |
| Nov 2026 | Low-dose lithium (Buffalo) | Keep vulnerable cells alive | Cell survival & anti-apoptosis | 1 | 15 | NCT04273932 | 22 Oct 2026 |
| Dec 2026 | Exidavnemab (EXIST) | Clear the bad protein | Synuclein misfolding & spread | 2 | 38 | NCT06671938 | 19 Oct 2026 |
| Dec 2026 | N-DOSE nicotinamide riboside dose-finding | Help cells clean up | Mitochondria & energy | 2 | 81 | NCT05589766 | 22 Oct 2026 |
| Jan 2027 | N-acetylcysteine (Monti) | Help cells clean up | Oxidative stress | 2 | 50 | NCT02445651 | 22 Oct 2026 |
| Mar 2027 | Aspen ASPIRO: patient-own-cell neurons | Replace or repair what's lost | Cell replacement | 2 | 15 | NCT06344026 | 19 Oct 2026 |
| Mar 2027 | exPDite-2 bemdaneprocel Phase 3 | Replace or repair what's lost | Cell replacement | 3 | 102 | NCT06944522 | 18 Oct 2026 |
| Mar 2027 | BEACON BIIB122 in LRRK2 carriers | Treat the inherited causes | LRRK2 | 2 | 50 | NCT06602193 | 19 Oct 2026 |
| Mar 2027 | MOST-ABLE: oral semaglutide (Osaka) | Look beyond the brain | Metabolic drug repurposing | 2 | 99 | jRCT2051230090 | 19 Oct 2026 |
| Apr 2027 | Radotinib Phase 2 (France) | Keep vulnerable cells alive | Cell survival & anti-apoptosis | 2 | 43 | NCT04691661 | 22 Oct 2026 |
| May 2027 | DAPA-PD (dapansutrile) | Look beyond the brain | Inflammation & immunity | 2 | 36 | NCT07157735 | 18 Oct 2026 |
| Aug 2027 | BHV-8000 (TYK2/JAK1 inhibitor) | Look beyond the brain | Inflammation & immunity | 3 | 550 | NCT06976268 | 19 Oct 2026 |
| Sep 2027 | RNDP-001 (Kenai) REPLACE | Replace or repair what's lost | Cell replacement | 2 | 12 | NCT07106021 | 19 Oct 2026 |
| Nov 2027 | NOSE-PD: nasal insulin plus glutathione | Help cells clean up | Oxidative stress | 2 | 56 | NCT05266417 | 18 Oct 2026 |
| Dec 2027 | NEU-411 (NEULARK) | Treat the inherited causes | LRRK2 | 2 | 150 | NCT06680830 | 18 Oct 2026 |
| Dec 2027 | Mass General autologous iPSC implant | Replace or repair what's lost | Cell replacement | 1 | 8 | NCT06687837 | 19 Oct 2026 |
| Dec 2027 | UC San Diego CT1-DAP001 donor iPSC cells | Replace or repair what's lost | Cell replacement | 1 | 7 | NCT06482268 | 19 Oct 2026 |
| Jun 2028 | ACI-7104 VacSYn Phase 2 | Clear the bad protein | Synuclein misfolding & spread | 2 | 150 | NCT06015841 | 19 Oct 2026 |
| Aug 2028 | REGENERATE-PD AB-1005 | Replace or repair what's lost | Growth factors | 2 | 127 | NCT06285643 | 18 Oct 2026 |
| Dec 2028 | RO7568282 (TARBELA-PD, NLRP3) | Look beyond the brain | Inflammation & immunity | 2 | 474 | NCT07781644 | 19 Oct 2026 |
| Dec 2028 | Brigham and Women's autologous iPSC dopamine cells | Replace or repair what's lost | Cell replacement | 1 | 12 | NCT06422208 | 19 Oct 2026 |
| Feb 2029 | ASPro-PD: ambroxol Phase 3 | Help cells clean up | Lysosome & GBA | 3 | 330 | NCT05778617 | 19 Oct 2026 |
| Jun 2029 | PARAISO prasinezumab Phase 3 | Clear the bad protein | Synuclein misfolding & spread | 3 | 900 | NCT07174310 | 18 Oct 2026 |
| Jun 2029 | ALN-SNCA (Regeneron siRNA) | Clear the bad protein | Synuclein lowering | 1 | 46 | NCT07216066 | 19 Oct 2026 |
| Aug 2029 | PRISMS: adalimumab in RBD | Behind the scenes | Trial methods & regulation | 2 | 108 | NCT06996652 | 18 Oct 2026 |
| Jul 2030 | LY3962681 (Lilly siRNA) | Clear the bad protein | Synuclein lowering | 1 | 124 | NCT06565195 | 19 Oct 2026 |
| Dec 2030 | PreCoDe: prasinezumab in GBA carriers | Clear the bad protein | Synuclein misfolding & spread | 2 | 120 | NCT07055087 | 22 Oct 2026 |